Table 2.
Characteristics of 107 patients in the I/O analysis
| All (n=107) | Deleterious DDR (n=19) | Wild type/VUS DDR (n=88) | |
| Age at start of treatment (years), median (range) | 61 (40–81) | 60 (40–74) | 61 (44–81) |
| Gender (male) | 78 (73%) | 13 (68%) | 65 (74%) |
| Nephrectomy | 100 (93%) | 18 (95%) | 82 (93%) |
| IMDC risk score at starting I/O therapy | |||
| Favorable | 23 (21%) | 2 (11%) | 21 (24%) |
| Intermediate | 65 (61%) | 15 (78%) | 50 (57%) |
| Poor | 19 (18%) | 2 (11%) | 17 (19%) |
| I/O therapy type | |||
| Anti-PD-1 monotherapy | 61 (57%) | 10 (53%) | 51 (58%) |
| Anti-PD-L1 monotherapy | 12 (11%) | 3 (16%) | 9 (10%) |
| Anti-PD-1+anti-CTLA-4 | 32 (30%) | 5 (26%) | 27 (31%) |
| Anti-PD-1+anti-PD-L1 | 2 (2%) | 1 (5%) | 1 (1%) |
| I/O therapy category | |||
| Monotherapy | 73 (68%) | 13 (68%) | 60 (68%) |
| Combination | 34 (32%) | 6 (32%) | 28 (32%) |
| Line of I/O therapy | |||
| First line | 40 (37%) | 8 (42%) | 32 (36%) |
| ≥Second line | 67 (63%) | 11 (58%) | 56 (64%) |
CTLA-4, cytotoxic T-lymphocyte-associated protein-4; DDR, DNA damage repair; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; I/O, immune-oncology; PD-1, programmed cell death-1; PD-L1, programmed cell death-ligand 1; VUS, variants of unknown significance.